文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肝细胞癌中的细胞外基质:机制与治疗弱点。

The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability.

机构信息

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

出版信息

Cell Rep Med. 2023 Sep 19;4(9):101170. doi: 10.1016/j.xcrm.2023.101170. Epub 2023 Aug 30.


DOI:10.1016/j.xcrm.2023.101170
PMID:37652015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10518608/
Abstract

The tumor microenvironment (TME) is influenced by a "disorganized" extracellular matrix (ECM) that sensitizes cancer cells toward mechanical stress, signaling, and structural alterations. In hepatocellular carcinoma (HCC), lack of knowledge about key ECM proteins driving the TME refractory to targeted therapies poses a barrier to the identification of new therapeutic targets. Herein, we discuss the contributions of various ECM components that impact hepatocytes and their surrounding support network during tumorigenesis. In addition, the underpinnings by which ECM proteins transduce mechanical signals to the liver TME are detailed. Finally, in view of the bidirectional feedback between the ECM, transformed hepatocytes, and immune cells, we highlight the potential role of the ECM disorganization process in shaping responses to immune checkpoint inhibitors and targeted therapies. Our comprehensive characterization of these ECM components may provide a roadmap for innovative therapeutic approaches to restrain HCC.

摘要

肿瘤微环境(TME)受“紊乱”的细胞外基质(ECM)影响,使癌细胞对机械应激、信号转导和结构改变敏感。在肝细胞癌(HCC)中,缺乏关于驱动 TME 对靶向治疗产生抗性的关键 ECM 蛋白的知识,这是识别新治疗靶点的障碍。本文讨论了各种 ECM 成分在肿瘤发生过程中对肝细胞及其周围支持网络的影响。此外,还详细阐述了 ECM 蛋白如何将机械信号转导到肝 TME。最后,鉴于 ECM、转化的肝细胞和免疫细胞之间的双向反馈,我们强调了 ECM 紊乱过程在塑造对免疫检查点抑制剂和靶向治疗的反应中的潜在作用。我们对这些 ECM 成分的全面描述可能为创新的治疗方法提供了一个路线图,以抑制 HCC。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/a9cb92a6a865/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/8a95cd6cac85/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/9c35477aac3e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/6277be2137a3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/a9cb92a6a865/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/8a95cd6cac85/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/9c35477aac3e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/6277be2137a3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa18/10518608/a9cb92a6a865/gr3.jpg

相似文献

[1]
The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability.

Cell Rep Med. 2023-9-19

[2]
Unveiling the Role of Mechanical Microenvironment in Hepatocellular Carcinoma: Molecular Mechanisms and Implications for Therapeutic Strategies.

Int J Biol Sci. 2024

[3]
Agrin Mediates Angiogenesis in the Tumor Microenvironment.

Trends Cancer. 2020-2

[4]
Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix.

Front Immunol. 2023

[5]
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.

J Hepatol. 2023-4

[6]
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.

Front Immunol. 2023

[7]
Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review.

Int J Nanomedicine. 2022

[8]
Extracellular matrix remodeling in the tumor immunity.

Front Immunol. 2023

[9]
Tumor decellularization reveals proteomic and mechanical characteristics of the extracellular matrix of primary liver cancer.

Biomater Adv. 2023-3

[10]
Extracellular matrix and its therapeutic potential for cancer treatment.

Signal Transduct Target Ther. 2021-4-23

引用本文的文献

[1]
Collagen heterogeneity: a barrier and bridge driving tumor immune microenvironment remodeling.

Immunol Res. 2025-9-9

[2]
Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application.

Front Immunol. 2025-8-13

[3]
Single-Cell Transcriptomic Analysis of Different Liver Fibrosis Models: Elucidating Molecular Distinctions and Commonalities.

Biomedicines. 2025-7-22

[4]
Nanodelivery of Y-27632 by RGD-modified liposome enhances radioimmunotherapy of hepatocellular carcinoma via tumor microenvironment matrix stiffness reprogramming.

Theranostics. 2025-7-28

[5]
Liver-Specific Extracellular Matrix Enables High-Fidelity Patient-Derived Hepatocellular Carcinoma Xenograft Models.

Biomater Res. 2025-8-21

[6]
Hypoxia-mediated HES4 promotes the proliferation and motility of hepatocellular carcinoma cell by enhancing COL4A2 transcription.

Discov Oncol. 2025-7-25

[7]
The mechanobiology of extracellular matrix: a focus on thrombospondins.

Cell Commun Signal. 2025-7-25

[8]
Correlation of radiotherapy, targeted therapy, and immunotherapy with hepatocellular carcinoma recurrence.

World J Gastrointest Oncol. 2025-7-15

[9]
Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets.

MedComm (2020). 2025-7-11

[10]
The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional Chinese medicine.

Mol Cancer. 2025-6-10

本文引用的文献

[1]
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

NEJM Evid. 2022-8

[2]
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer.

Nat Commun. 2022-12-7

[3]
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.

Nature. 2022-10

[4]
Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances.

Adv Cancer Res. 2022

[5]
Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma.

Cancers (Basel). 2022-4-9

[6]
Osteopontin promotes hepatocellular carcinoma progression through inducing JAK2/STAT3/NOX1-mediated ROS production.

Cell Death Dis. 2022-4-13

[7]
PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.

Gut. 2022-12

[8]
Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches.

Cell. 2022-1-20

[9]
Cancer statistics, 2022.

CA Cancer J Clin. 2022-1

[10]
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

J Hepatol. 2022-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索